Medtronic teams up with ARCA for a-fib trial

ARCA Biopharma ($ABIO) is planning a Phase IIb/III trial of Gencaro, an investigational atrial fibrillation drug, and Medtronic ($MDT) has signed on to outfit each patient with an implanted CRT-D, measuring the therapy's effect. ARCA is starting with 200 patients in Phase IIb before, depending on results, rolling the study into a 420-patient Phase III trial. More

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.